Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur)(Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur))

概要

基本信息

药物类型

预防性疫苗、多价疫苗、mRNA疫苗

别名

MRT 5410、MRT-5410、MRT5410

靶点-

作用方式

刺激剂

作用机制

免疫刺激剂

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

4

项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的临床试验

NCT05624606

/ Completed临床1/2期

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adults Aged 18 Years and Older

The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD [adults ≥ 65 years of age only], or RIV4) in adults 18 years of age and older.

开始日期2022-11-28

申办/合作机构

Sanofi Pasteur SA

NCT02554409

/ CompletedN/A

Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry Protocol

The Sanofi Pasteur Fluzone Intradermal Quadrivalent vaccine (Fluzone QIV-ID) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect to collect and analyze information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes on pregnant women exposed to Fluzone QIV-ID vaccine.

开始日期2015-10-13

申办/合作机构

Sanofi Pasteur SA

NCT02451358

/ Completed临床3期

Immunogenicity and Safety of a Single Dose or Two Doses Given 28 Days Apart of a Quadrivalent Influenza Vaccine Administered Via the Intramuscular Route in Subjects Aged 6 Months or Older in India

The aim of the study was to generate immunogenicity and safety data in the whole population to support registration of the Quadrivalent Influenza Vaccine (QIV) in India:
Primary objective:
To describe in each age group the immune response induced by a single injection (participants aged >9 years) or 2 injections (participants aged 6 months to 8 years) of QIV.
Secondary objective:
To describe in each age group the safety profile of QIV.

开始日期2015-07-27

申办/合作机构

Sanofi Pasteur SA

100 项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的临床结果

登录后查看更多信息

100 项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的转化医学

登录后查看更多信息

100 项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的专利（医药）

登录后查看更多信息

100 项与 Quadrivalent Influenza mRNA Vaccine(Sanofi Pasteur) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
流感病毒感染	临床3期	美国	Sanofi Pasteur SA	2010-10-01
接种疫苗	临床2期	美国	Sanofi Pasteur SA	2022-11-28
接种疫苗	临床2期	波多黎各	Sanofi Pasteur SA	2022-11-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02451358 (CTgov)	临床3期	流感病毒感染	400	Quadrivalent Inactivated Influenza Vaccine (Quadrivalent Influenza Vaccine Group 1: 6 to 35 Months)	積範襯醖繭糧艱壓壓齋(衊廠築襯鏇壓餘餘鹽簾) = 遞繭築鏇築艱遞獵範積膚襯鹹壓夢繭蓋觸鏇積 (蓋夢糧艱鑰夢糧醖齋壓, 衊壓膚鑰鑰觸築憲衊網 ~ 繭鑰願築觸窪繭獵艱淵) 更多	-	2018-03-01
				Quadrivalent Inactivated Influenza Vaccine (Quadrivalent Influenza Vaccine Group 2: 3 to 8 Years)	積範襯醖繭糧艱壓壓齋(衊廠築襯鏇壓餘餘鹽簾) = 艱鑰簾網糧鹽蓋艱鬱鹹膚襯鹹壓夢繭蓋觸鏇積 (蓋夢糧艱鑰夢糧醖齋壓, 鑰構鬱獵鏇艱繭鹹製顧 ~ 夢襯繭鬱網淵願鏇鬱壓) 更多